Vivos Therapeutics, Inc.·4

Feb 28, 6:50 PM ET

Amman Bradford K. 4

4 · Vivos Therapeutics, Inc. · Filed Feb 28, 2022

Insider Transaction Report

Form 4
Period: 2022-02-25
Amman Bradford K.
Chief Financial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-02-25$3.27/sh+50,000$163,50050,000 total
    Exercise: $3.27Exp: 2027-02-25Common Stock (50,000 underlying)
Footnotes (1)
  • [F1]50,000 stock options granted on February 25, 2022. One-fifth vested immediately and one-fifth vests annually on each anniversary date through February 25, 2026.

Documents

1 file
  • 4
    ownership.xmlPrimary